Am J Transplant, Volume 21, Suppl 3 Archives - Page 73 of 139 - ATC Abstracts

2021 American Transplant Congress
Nanoparticle Mediated Drug Delivery for Lung Transplantation
P. M. Patel¹, S. Jung², C. L. Miller¹, J. M. O¹, T. Costa¹, A. Dehnadi¹, I. Hanekamp¹, X. F. Li², L. Jiang², H. Ichimura², A. Azimzadeh¹, J. C. Madsen³, R. Abdi²
¹Surgery, Center for Transplantation Sciences, Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²Medicine, Transplant Research Center, Brigham and Women's Hospital, Boston, MA, ³Surgery, Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, MA
*Purpose: Severe primary graft dysfunction (PGD) affects 30% of lung transplant patients. Pulmonary alveolar macrophages play a significant role in lung PGD, but systemic immunotherapy…
2021 American Transplant Congress
Prospective Intensive Monitoring for Anamnestic DSA Responses Allows Near Elimination of Early Clinical AMR
M. McGowan¹, A. Bickenbach¹, A. R. Shields², R. R. Alloway¹, P. Brailey¹, E. Portwood¹, C. Alquist¹, A. Christianson¹, B. Abu Jawdeh¹, M. Cuffy¹, J. Kremer², S. Bumb¹, A. Govil¹, M. Anand¹, T. Kaur¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²Christ Hospital, Cincinnati, OH
*Purpose: Anamnestic donor specific antibody (aDSA) responses can result in severe, graft threatening antibody-mediated rejection (AMR). We hypothesized that intensive DSA monitoring (IDM) for aDSA…
2021 American Transplant Congress
High and Low Frequency Domino Liver Transplantation Centers Demonstrate Similar Outcomes
J. Panichella, H. Resweber, H. Curtis, K. Nguyen, A. Di Carlo, S. Karhadkar
Temple University School of Medicine, Philadelphia, PA
*Purpose: For patients with transthyretin (TTR) Amyloidosis, the only disease modifying treatment is an orthotopic liver transplant. However, because of the nature of this disease,…
2021 American Transplant Congress
Cellular Landscape of Steatotic Livers Revealed by Single-nuclei Rna Sequencing
C. Kuscu¹, C. Kuscu¹, A. Shetty², E. Bardhi³, T. Rousselle⁴, J. Eason¹, M. Sraj⁵, D. Maluf⁶, V. Mas⁴
¹Surgery, James D Eason Transplant Institute, Memphis, TN, ²University of Maryland, Institute for Genome Sciences, Baltimore, MD, ³Program in Transplantation - University of Maryland, Baltimore, MD, ⁴Surgery, Division of Surgical Science, Baltimore, MD, ⁵Surgery, University of Maryland, Baltimore, MD, ⁶Surgery, Program in Transplantation - University of Maryland, Baltimore, MD
*Purpose: Hepatic IRI represents a barrier to the use of available organs for transplant, particularly fatty livers. We aimed to discern the cellular subsets and…
2021 American Transplant Congress
Launching a National Living Donor Registry
J. E. Milton¹, M. Cooper², B. Hippen³
¹Transplant Center, University of Texas Health San Antonio, San Antonio, TX, ²MedStar Georgetown Transplant Institute, Washington, Colombia, ³Metrolina Nephrology Associates, PA, Charlotte, NC
*Purpose: The National Donate Life Living Donor Registry launching in 2021 will allow 4000 persons a day the opportunity to become a living donor offering…
2021 American Transplant Congress
Frequency and Types of Pharmacist Interventions and Risk Assessments Occurring During the 12-Month Transafe Rx Randomized Controlled Trial
H. M. Gonzales, J. N. Fleming, D. J. Taber
MUSC, Charleston, SC
*Purpose: Clinical pharmacists have unique education and training to identify and mitigate medication (med) safety issues in high-risk populations, such as kidney transplant (KTX). The…
2021 American Transplant Congress
Recipient and Kidney Allograft Outcomes from Hypertensive Live-Donor in the United States
S. Riad¹, S. Jackson², D. Vock³, A. Matas⁴
¹Medicine, University of Minnesota, Minneapolis, MN, ²Complex Care Analytics, M-Health Fairview, Minneapolis, MN, ³School of Public Health, University of Minnesota, Minneapolis, MN, ⁴Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Controlled hypertension in select prospective kidney donors is no longer an exclusion criterion for donation. We examined the association between pre-donation hypertension (HTN) and…
2021 American Transplant Congress
Experiences of Women Trainees in Transplant Surgery
A. E. Gomez-Rexrode¹, D. E. Cassidy¹, M. S. Anderson², J. R. Santos-Parker¹, L. M. McElroy³, S. A. Waits², V. S. Valbuena²
¹University of Michigan Medical School, Ann Arbor, MI, ²Department of Surgery, University of Michigan Health System, Ann Arbor, MI, ³Department of Surgery, Duke University Medical Center, Durham, NC
*Purpose: To assess the unique experiences of women surgical trainees to better understand the recruitment and training strategies needed to ensure meaningful progress toward gender…
2021 American Transplant Congress
27 Months Follow Up of a Cohort in the Transplant Continuum After Using a New Electronic Medical Record Tool to Document Transplant Option Discussions Among Patients with EGFR <20 Ml/min/1.73m2
A. A. Yishak¹, M. S. Bhatnagar², A. V. Tomimatsu³, R. La Londe⁴, E. Clark⁵, K. B. Rubenstein⁶, S. Vupputuri⁶
¹MAPMG, McLean, VA, ²Kaiser Permanente |, Oakland, CA, ³Kaiser Permanente, Oakland, CA, ⁴Kaiser Permanente, Oakland,, CA, ⁵Kaiser Permanente, Hyattsville, MD, ⁶MAPRI, Rockville, MD
*Purpose: The purpose of this study was to assess: 1) the documentation of transplant option discussions; 2) the number of members listed & transplanted preemptively;…
2021 American Transplant Congress
The Development and Characterization of AT1501, an Anti CD40L Antibody Lacking Fc Effector Function
S. Perrin¹, A. Gill², C. Gill², F. Vieira², K. Thompson², J. Lincecum², B. Jiang²
¹Novus Therapeutics, Irvine, CA, ²ALS Therapy Development Institute, Cambridge, MA
*Purpose: CD40L is a costimulatory type II membrane receptor for CD40. The binding of CD40L on T helper cells to CD40 on antigen presenting cells…